Skip to main content
EQL Pharma AB logo

EQL Pharma AB — Investor Relations & Filings

Ticker · EQL ISIN · SE0005497732 LEI · 549300Q8B2D2AE8GCW21 ST Manufacturing
Open in API
Filings indexed 57 across all filing types
Latest filing 2024-12-10 M&A Activity
Country SE Sweden
Listing ST EQL

About EQL Pharma AB

https://eqlpharma.com/en/

EQL Pharma AB is a pharmaceutical company that develops, markets, and sells generic and specialty medicines. The company's strategy centers on identifying and developing "niche generics," which are medically equivalent to originator drugs but face limited competition after patent expiration. Its business operations also include specialty pharmaceuticals and the parallel import of medicines. EQL Pharma emphasizes cost-efficiency and collaborates with a global network of development partners. The company serves pharmacies and hospitals, primarily in the Nordic markets, maintaining a portfolio of marketed products while cultivating an extensive pipeline of new medicines.

Recent filings

Filing Released Lang Actions
Correction: EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals
M&A Activity Classification · 1% confidence The document is a press release announcing that EQL Pharma AB has signed a binding asset purchase agreement to acquire a portfolio of pharmaceuticals for DKK 120 million. This transaction involves fundraising/financing discussions (mandating an advisor for new debt financing) and a significant corporate action (acquisition). This falls directly under the definition of 'Capital/Financing Update' (CAP) as it details a major financing activity related to an acquisition, or potentially 'Regulatory Filings' (RNS) if it were purely a disclosure. However, given the focus on the financing arrangement and the material transaction value, CAP is the most specific fit, as it relates to capital structure changes/fundraising to support the deal. It is not an ER, IR, 10-K, or a simple announcement of a report (RPA).
2024-12-10 English
Rättelse: EQL Pharma AB (publ) ingår ett inkråmsöverlåtelseavtal avseende förvärv av en portfölj med originalläkemedel
Capital/Financing Update Classification · 1% confidence The document is a press release ("Pressmeddelande") from EQL Pharma AB dated December 10, 2024. The core content announces that the company has entered into a binding asset transfer agreement to acquire a portfolio of original drugs for DKK 120 million. It details the financial impact, strategic rationale, and mentions that the company is exploring debt financing options for the acquisition. This clearly falls under an announcement related to corporate financing, capital structure changes, or significant transactions that impact the company's structure and funding. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific, material corporate action involving financing and acquisition.
2024-12-10 Swedish
EQL Pharma AB (publ) ingår ett inkråmsöverlåtelseavtal avseende förvärv av en portfölj med originalläkemedel
M&A Activity Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a significant corporate action: the signing of an asset transfer agreement to acquire a portfolio of original drugs for DKK 120 million. It details the financial impact, strategic rationale, and financing plans (mandating an advisor for debt financing). This type of announcement, detailing a major transaction like an acquisition or significant financing activity, aligns best with the 'Capital/Financing Update' (CAP) category, as it directly concerns changes to the company's structure and funding strategy, although it is also related to M&A. Given the focus on the financing required to complete the acquisition and the overall capital structure implications, CAP is a strong fit. However, since the core event is an acquisition/takeover proposal (even if it's an asset purchase), 'M&A Activity' (TAR) is also highly relevant. Since the text explicitly mentions the agreement to acquire assets and the financing required, and it is presented as a formal press release detailing a transaction, TAR (Merger/Takeover Activity) is the most precise fit for an acquisition announcement, even if it's an asset deal rather than a full company takeover. The document is not a full financial report (10-K, IR) or a simple announcement of a report (RPA).
2024-12-10 Swedish
EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals
M&A Activity Classification · 1% confidence The document is a press release announcing that EQL Pharma AB has signed a binding asset purchase agreement to acquire a product portfolio for DKK 120 million. This transaction involves fundraising/financing discussions (mandating an advisor for new debt financing) and a significant corporate transaction (acquisition/merger activity). Since the core subject is the acquisition of assets and the associated financing evaluation, the most fitting category is Capital/Financing Update (CAP) or M&A Activity (TAR). Given the explicit mention of signing an 'asset purchase agreement' and the financial details surrounding the transaction, TAR (Merger/Takeover Activity) is highly relevant. However, the text also details the financing plan for the acquisition ('evaluate alternatives for a new debt financing'), which strongly aligns with CAP (Capital/Financing Update). Since the primary action described is the agreement to purchase assets, which is a form of M&A, and the financing is secondary to the deal itself, TAR is a strong candidate. Looking at the definitions, TAR covers 'merger proposals or takeover bids'. An asset purchase agreement is a form of M&A. CAP covers 'fundraising, financing activities, or capital structure changes'. Because the document details both the transaction (TAR) and the financing evaluation (CAP), I must choose the primary focus. The headline focuses on the 'acquisition'. I will classify this as M&A Activity (TAR), as the acquisition is the central event being announced, even though financing is mentioned. If TAR is too narrow, CAP is the next best fit. Given the context of corporate transactions, TAR is preferred over CAP for an acquisition announcement.
2024-12-10 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for EQL Pharma covering the period April to September 2024. It contains comprehensive financial statements, including income statements, balance sheet data, cash flow analysis, and detailed management commentary on business performance, product pipelines, and market dynamics. It is clearly a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2024
2024-11-06 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'Interim Report' and covers the period from April to September 2024. It contains comprehensive financial statements, including net sales, gross profit, operating profit, and cash flow data for the specified periods. It also includes detailed management commentary, business updates, and pipeline information. As it is a substantive financial report for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report (IR). H1 2025
2024-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.